Hubei Biocause Pharmaceutical (000627) — Long-term Investment Intensity
Hubei Biocause Pharmaceutical (000627) has a Long-term Investment Intensity of 46.6% as of September 2024. Long-term investments of CN¥132.77 Billion represent 46.6% of total assets of CN¥285.15 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Hubei Biocause Pharmaceutical (000627) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Hubei Biocause Pharmaceutical Long-term Investment Intensity (2015–2023)
This chart shows how Hubei Biocause Pharmaceutical's Long-term Investment Intensity has evolved across 9 annual periods from 2015 to 2023. As of September 2024, the intensity stands at 46.6%, reflecting long-term investments of CN¥132.77 Billion against total assets of CN¥285.15 Billion CNY. Explore Hubei Biocause Pharmaceutical cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Hubei Biocause Pharmaceutical (2015–2023)
The table below presents the year-by-year Long-term Investment Intensity for Hubei Biocause Pharmaceutical from 2015 to 2023, covering 9 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see 000627 market cap overview.
| Year | LT Investment Intensity | LT Investments (CNY) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2023 | 45.5% | CN¥137.49 Billion | CN¥301.94 Billion | ▼ -0.9 pp |
| 2022 | 46.4% | CN¥133.91 Billion | CN¥288.60 Billion | ▲ +1.2 pp |
| 2021 | 45.2% | CN¥119.17 Billion | CN¥263.90 Billion | ▲ +40.0 pp |
| 2020 | 5.2% | CN¥12.39 Billion | CN¥239.40 Billion | ▼ -1.2 pp |
| 2019 | 6.4% | CN¥13.10 Billion | CN¥205.27 Billion | ▼ -36.8 pp |
| 2018 | 43.2% | CN¥76.96 Billion | CN¥178.25 Billion | ▼ -1.1 pp |
| 2017 | 44.2% | CN¥62.12 Billion | CN¥140.42 Billion | ▼ -10.1 pp |
| 2016 | 54.3% | CN¥64.05 Billion | CN¥117.88 Billion | ▲ +6.2 pp |
| 2015 | 48.2% | CN¥1.16 Billion | CN¥2.41 Billion | — |